Arcturus, a new COVID-19 sub-variant, has caught the attention of the World Health Organization (WHO). The new omicron variant, XBB.1.16, causes familiar symptoms of previous variants of coronavirus.

The Arcturus subvariant stems from the Omicron strain of Covid-19 and is known as XBB.1.16 since it descends from the recombinant variant XBB, which combines two sublineages of Omicron BA.2.

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...

Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including mRNA, siRNA, replicon RNA, asRNA, DNA, and gene editing therapeutics.

São Paulo's Municipal Health Secretariat reported this week the first case of variant XBB.1.16 of Covid-19, also known as Arcturus in a 75-year-old man, bedridden and with comorbidities ...

Publications of the Astronomical Society of the Pacific Vol. 111, No. 759, May 1999 Adaptive Optics Observations of Arcturus... Adaptive Optics Observations of Arcturus using the Mount Wilson 100 Inch ...

SAN DIEGO, April 10, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of ...

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago.

AlphaQuest LLC cut its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 63.9% in the fourth quarter, according to its most recent 13F filing with the Securities ...

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities ...